Filana Therapeutics Inc (FLNA)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$0.82-0.99%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · FLNA
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance is still in the top half of its industry but slipped notably this past month — worth watching.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -89.5% |
| Our one-year growth estimate | diamond | Not available |
Growth built into the price is above our model estimate.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
A comparable growth gap is not available.
The one-year revenue growth assumption on Valuation.
Model as of 2026-09-04 · Compared with 398 industry peers · Company calendar date is not available
FLNA — officer change
Dated 2026-06-15
The excerpt is incomplete and does not provide specific details about the event.
Why it matters: Updates from this conference could help Filana in the TSC community. They may show scientific progress.
Supportive ifFilana shares new partnerships from the conference. These will help their program.
Worry ifNo major updates or partnerships were shared. This shows little engagement.
Why it matters: Good cash management is key for funding operations and research.
Watch forFilana reports cash used in operations below the guided range of $11M to $15M for the second half of 2026.
Also watch forCash used in operations is higher than expected. This shows possible money problems.
Why it matters: A resolution could reduce financial worries. It may also make investors feel better.
Supportive ifThe court agrees to the settlement of the securities case. This confirms the resolution.
Worry ifThe litigation is still unresolved. New claims could arise, raising legal risks.
Why it matters: Higher cash burn could strain liquidity and impact operations. It is critical for managing financial health.
Worry ifNet cash used in operations for H2 2026 reported below $15 million.
Less concerning ifNet cash used in operations is over $15 million, showing a higher burn rate than expected.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$260 on $10,000 · ±2.6% | How much price usually moves either way. |
| Bad day | $699 loss on $10,000 · 7.0% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $6,554 loss on $10,000 · 65.5% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: Meeting the cash use target shows better management of operational costs. This impacts financial health.
Supportive ifCash use in operations for Q2 falls between $14 million and $17 million.
Worry ifThe company spends over $17 million on operations. This shows poor cost management.
Why it matters: Progress on litigation could reduce financial risks. It impacts investor confidence and future cash flow.
Supportive ifManagement says they have settled the $31.25 million legal case.
Worry ifNo news on the legal case resolution. The $31.25 million issue remains.
Why it matters: If healthcare sector revenue growth speeds up, it could boost Filana's performance. This would suggest a better market environment.
Supportive ifHealthcare sector revenue growth returns to above 10% year over year.
Worry ifHealthcare sector revenue growth remains below 10% year over year.
Why it matters: Higher cash burn could hurt liquidity. This may affect the company's ability to fund operations.
Worry ifNet cash used in operations for the second half of 2026 is reported above $15 million.
Less concerning ifNet cash used in operations stays below $11 million for the second half of 2026.